Pioneering Quantum Partnership Aims for Biomaterials Growth
Marine Biologics has struck an exclusive partnership with Molecular Quantum Solutions that makes it the sole commercialization channel for...
Jon Napitupulu
New Phase 1 Study Results for NBTXR3 in Resistant Melanoma
Nanobiotix reported new Phase 1 data in primary cutaneous melanoma showing that a one-time intratumoral injection of JNJ-1900 (NBTXR3),...
Rezolute Reports Q4 & Full Year Fiscal 2025 Financials
Rezolute reported fiscal 2025 results alongside two pivotal clinical inflection points for its lead asset, ersodetug: completion of enrollment...
Idorsia’s Jeraygo Approved for Resistant Hypertension
Swissmedic has approved Idorsia’s Jeraygo (aprocitentan) for resistant hypertension in adults, to be used alongside at least three antihypertensive...
AL Amyloidosis Trial Surpasses 50% Enrollment Milestone
Immix Biopharma has crossed the 50% enrollment mark in NEXICART-2, a U.S. multi-site phase 1/2 trial with a registrational...
Lipella Sees Positive Final Results for LP-10 Drug Study
Lipella Pharmaceuticals reported positive final results from a completed phase 2a multicenter, dose‑ranging study of LP‑10, a liposomal tacrolimus...
Successful Accreditation for Plus Therapeutics’ CNSide Lab
CNSide Diagnostics, a wholly owned subsidiary of Plus Therapeutics, has received a CMS certificate of accreditation under CLIA for...
Epitopea Adds Four Immunology Experts to Scientific Board
Epitopea has expanded its scientific advisory board with four high-profile appointments—Nahum Sonenberg, Nina Bhardwaj, Margaret Callahan, and Craig L....
Roche’s New Merger with 89bio Targets Promising MASH Therapy
Roche has signed a definitive agreement to acquire 89bio for $14.50 per share in cash, plus a non-tradeable contingent...
EuroAPI’s New Climate Targets Approved by SBTi Initiative
EUROAPI’s near-term science-based climate targets have been validated by the Science Based Targets initiative, marking a formal commitment to...